KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE). Its lead product, EKTERLY (sebetralstat), received FDA approval in July 2025 and the company has begun U.S. commercial operations while also pursuing ex-U.S. partnering opportunities.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSales of EKTERLY in the U.S. following FDA approval.
Upfront, milestone, and royalty income from regional licensing deals.
Research and development work on sebetralstat and other pipeline candidates.
Asiakkaat
The core customer base is allergists and immunologists, who account for most HAE prescribing and claims in the U.S. EKTERLY is ultimately bought through the specialty pharmacy and payer channel, with access and reimbursement decisions shaping uptake. Outside the U.S., KalVista also serves regional pharmaceutical partners that commercialize or seek approval for sebetralstat in their own markets.
Allergists and immunologists who prescribe EKTERLY for acute HAE attacks and drive adoption.
Patients who receive EKTERLY through specialty pharmacy channels and benefit programs.
Organizations that determine formulary access, reimbursement, and patient out-of-pocket costs.
Channel partners that dispense product, manage inventory, and support distribution.
Companies such as Kaken and Pendopharm that commercialize or seek approval in local markets.
Strategia
KalVista’s strategy is to convert EKTERLY from a development asset into a commercial product in the U.S. while using partnerships to extend reach in non-U.S. markets. The company is also investing in market access, a specialty sales force, and manufacturing/supply capabilities to support launch execution and future label expansion.
Near-term value creation depends on converting FDA approval into prescriptions and payer coverage.
Licensing reduces the cost of global expansion while preserving upside through milestones and royalties.
Commercial success depends on reliable manufacturing, regulatory maintenance, and product availability.
Maantiede
KalVista’s commercial focus is currently the United States, where EKTERLY launched after FDA approval in July 2025. The company is also building an international footprint through licensing agreements in Japan and Canada, while retaining manufacturing and regulatory responsibilities for those markets. Geography matters because near-term revenue is concentrated in the U.S., but future growth depends on partner-led expansion abroad.
Riskit
KalVista is still highly dependent on EKTERLY, so commercial uptake, payer access, and physician adoption will largely determine near-term performance. The company also faces typical biotech risks around funding needs, manufacturing reliability, regulatory execution, and competition from other HAE therapies. Because it is early in commercialization, execution risk is elevated and revenue visibility remains limited.
- Funding and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has a history of losses and may need more capital to support commercialization and R&D.
Kohdistuu: Operating cash needs and launch investment
- Dependence on EKTERLY commercializationVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company’s value and revenue base are concentrated in a single approved product.
Kohdistuu: U.S. launch and future ex-U.S. royalties
- Insufficient market acceptanceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Prescriber adoption and payer coverage determine whether the launch converts into durable sales.
Kohdistuu - Manufacturing and supply riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Product availability depends on third-party manufacturing and distribution execution.
Kohdistuu: EKTERLY supply chain
- Competitive pressure in HAEVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Other pharmaceutical companies market or develop therapies for the same indication.
Kohdistuu: HAE acute treatment market
Kirjanpito
Harkinnanvaraiset erätCo-pay assistance, prompt-payment discounts, distribution fees, and returns reduce gross sales to net product revenue.
Vaikutus: Can materially change reported EKTERLY revenue in early launch periods
Upfront and contingent payments from Kaken and other partners require judgment on recognition timing.
Vaikutus: Affects collaboration revenue and deferred revenue balances
R&D, manufacturing, and launch costs are accrued based on estimates and vendor activity.
Vaikutus: Can cause quarter-to-quarter expense volatility
The company has operating leases for office and laboratory space.
Vaikutus: Creates right-of-use assets and lease liabilities
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
BioCryst Pharmaceuticals, Inc
BCRX · Biological Products, (No Diagnostic Substances)
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE).
Milestone Pharmaceuticals Inc.
MIST · Pharmaceutical Preparations
KALA BIO, Inc
KALA · Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations
Palvella Therapeutics, Inc
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
Akebia Therapeutics, Inc.
AKBA · Pharmaceutical Preparations
Akebia Therapeutics is a U.S.-based biopharmaceutical company focused on kidney disease, with two commercial products and a pipeline aimed at rare kidney diseases and other renal-related indications.
Päivitetty: 24.9.2026